This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 167 entries.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is […]
#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and […]
Botanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US. Click here […]
Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million). Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation […]
Euroz Hartleys has published a research note on Botanix maintaining a price target of $0.80. The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™. Click here to read the full report.
Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation. Here’s an excerpt: “It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth […]
Botanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress. Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a […]
Botanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™. Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance. The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap […]
Euroz Hartleys has published a research note on Botanix forecasting strong sales momentum for Sofdra™. Click here to read the report.
